{"ctNumber":"2024-514043-29-00","ctStatus":"Authorised","startDateEU":"2022-09-21","decisionDate":"2024-07-19T16:48:14.133","publishDate":"2026-07-28T03:31:00.182628038","ctPublicStatusCode":5,"authorizedApplication":{"authorizedPartI":{"id":133894,"rowSubjectCount":0,"products":[{"id":556489,"part1MpRoleTypeCode":"2","productDictionaryInfo":{"productPharmForm":"PHF00007MIG","euMpNumber":"SCP138048","marketingAuthNumber":"-","prodAuthStatus":2,"activeSubstanceName":"CICLOSPORIN","euSubstNumber":"SUB06250MIG","productSubstances":[{"substancePk":"422835","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"CICLOSPORIN","substanceEvCode":"SUB06250MIG","synonyms":["CYCLOSPORIN A","CYCLOSPORINE","CICLOSPORINE","CYCLOSPORIN"]}],"atcCode":"L04AD01","atcName":"CICLOSPORIN\r","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"500","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"30","productChangedRelationMA":false,"maxTreatmentPeriod":60,"timeUnitCode":"1","scientificProductEvCode":"SCP138048","scientificProductPharmEvCode":"PHF00007MIG","devices":[],"characteristics":["6"],"routes":["ORAL USE"],"allSubstancesChemicals":true,"productName":"CICLOSPORIN\r","jsonActiveSubstanceNames":"ciclosporin","pharmaceuticalFormDisplay":"PHF00007MIG"},{"id":556490,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPharmForm":"N/A","euMpNumber":"N/A","marketingAuthNumber":"N/A","prodName":"Placebo of ILT-101","pharmForm":"N/A","activeSubstanceName":"N/A","euSubstNumber":"N/A","productOtherName":"N/A","authorisationCountryCode":"IS","nameOrg":"N/A","sponsorSubstanceCode":"N/A","atcCode":"N/A","atcName":"N/A","atcTermLevel":"N/A","activeSubstanceOtherDescriptiveName":"N/A"},"isPaediatricFormulation":false,"mpRoleInTrial":"3","timeUnitCode":"2","evCode":"N/A","miaNumber":"2023_200_1_2_3_10","devices":[],"characteristics":[],"routes":[],"allSubstancesChemicals":false,"productName":"Placebo of ILT-101","jsonActiveSubstanceNames":"n/a","pharmaceuticalFormDisplay":"N/A"},{"id":556491,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11428062","productPharmForm":"SOLUTION FOR INJECTION","euMpNumber":"PRD11428062","prodAuthStatus":1,"prodName":"ILT-101 liquide","pharmForm":"SOLUTION FOR INJECTION","sponsorProductCode":"ILT-101 ","activeSubstanceName":"ALDESLEUKIN","euSubstNumber":"SUB05303MIG","nameOrg":"ILTOO PHARMA","productSubstances":[{"productPk":"11428062","substancePk":"376734","nameOrg":"ILTOO PHARMA","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"ALDESLEUKIN","substanceEvCode":"SUB05303MIG"}],"atcCode":"L03AC01","atcName":"ALDESLEUKIN","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"Munit million units","maxDailyDoseAmount":"1","doseUomTotal":"Munit million units","maxTotalDoseAmount":"46","maxTreatmentPeriod":12,"timeUnitCode":"3","evCode":"PRD11428062","sponsorProductCodeEdit":"ILT-101 ","miaNumber":"2023_200_1_2_3_10","devices":[],"characteristics":["7","4"],"routes":["INTRAVENOUS"],"allSubstancesChemicals":false,"productName":"ILT-101 liquide","jsonActiveSubstanceNames":"aldesleukin","pharmaceuticalFormDisplay":"SOLUTION FOR INJECTION"}],"trialDetails":{"clinicalTrialIdentifiers":{"fullTitle":"DFIL2-REP - Study of the clinical and biological response to repeated administration of low-dose interleukin-2 in patients with type 1 diabetes who have retained residual insulin secretion","fullTitleTranslations":[{"id":11221790,"uuid":"c8e3758e-a283-4d87-96b3-c0b0c8936670","attributeTranslation":"Etude de la réponse clinique et biologique à l’administration répétée d’interleukine-2 à faible dose chez des patients présentant un diabète de type 1 ayant gardé une sécrétion résiduelle d’insuline","language":34,"languageDescription":"French (France)"}],"publicTitle":"DFIL2-REP - Study of the clinical and biological response to repeated administration of low-dose interleukin-2 in patients with type 1 diabetes who have retained residual insulin secretion","publicTitleTranslations":[{"id":11221799,"uuid":"09b4b025-191d-444b-bbc6-4e1250b0fcc9","attributeTranslation":"Etude de la réponse clinique\net biologique à l’administration répétée d’interleukine-2 à\nfaible dose chez des patients présentant un diabète de\ntype 1 ayant gardé une sécrétion résiduelle d’insuline","language":34,"languageDescription":"French (France)"}],"shortTitle":"P120142","secondaryIdentifyingNumbers":{"nctNumber":{"id":541550,"number":"NCT05153070"},"additionalRegistries":[]}},"trialInformation":{"trialCategory":{"isLowIntervention":false,"trialPhase":"4","trialCategory":"2","justificationForTrialCategory":"therapeutic use phase II","trialCategoryId":123401},"medicalCondition":{"partIMedicalConditions":[{"id":139859,"medicalCondition":"Patient with newly diagnosed (≤ 3 months) type 1 diabetes stage 3","medicalConditionTranslations":[{"id":11221765,"uuid":"dd206cf7-bd70-4336-aa43-aa6f218e5156","attributeTranslation":"Patient présentant un diabète de type 1 stade 3 de déclaration récente (≤ 3 mois)","language":34,"languageDescription":"French (France)"}],"isConditionRareDisease":false}]},"trialObjective":{"trialScopes":[{"code":"3","trialScopeId":406480}],"mainObjective":"Evaluation of the Tregs lymphocyte response profile between D63 and D70, after 5 administrations of low-dose IL-2 (1MUI/day) in patients with type 1 diabetes of recent onset who had received ciclosporin treatment for 2 months.","mainObjectiveTranslations":[{"id":11221798,"uuid":"bc8e5bc1-11f7-422b-823f-65bcedc2947b","attributeTranslation":"Évaluation du profil de la réponse des lymphocytes Tregs entre J63 et J70, après 5 administrations de faibles doses d’IL-2 (1MUI/jour) chez des patients ayant un diabète de type 1 de déclaration récente ayant reçu un traitement par ciclosporine pendant 2 mois.","language":34,"languageDescription":"French (France)"}],"secondaryObjectives":[{"id":476284,"number":1,"secondaryObjective":"Evolution of residual insulin secretion","secondaryObjectiveTranslations":[{"id":11221800,"uuid":"2d3a53aa-8735-4031-b80f-36acd4723228","attributeTranslation":"l’amélioration de la sécrétion résiduelle d’insuline ;","language":34,"languageDescription":"French (France)"}]},{"id":476285,"number":2,"secondaryObjective":"Change in Tregs values at M3 (J88), M6 (J179), M9 (J270), M12 (J361) and after treatment discontinuation at M18 (J536) and M24 (J719) compared to baseline and post ciclosporin values (J63)","secondaryObjectiveTranslations":[{"id":11221801,"uuid":"bd386e5f-6728-441c-a20f-ebfa9dcf945b","attributeTranslation":"Du taux des Tregs à M3, M6, M9, M12, M18 et M24 comparativement à la baseline et aux valeurs post ciclosporine (J63)","language":34,"languageDescription":"French (France)"}]},{"id":476286,"number":3,"secondaryObjective":"Compliance with ciclosporin and ILT-101/placebo","secondaryObjectiveTranslations":[{"id":11221802,"uuid":"235078ee-db32-4892-8d44-9466be2be75c","attributeTranslation":"De l’observance à la ciclosporine et à l’ILT-101/placebo","language":34,"languageDescription":"French (France)"}]},{"id":476287,"number":4,"secondaryObjective":"Tolerance of trial treatments from D1 to D719","secondaryObjectiveTranslations":[{"id":11221803,"uuid":"167b0ae3-074f-4e24-81bb-4ae40f936c61","attributeTranslation":"La tolérance des traitements à l’essai de J1 à J719","language":34,"languageDescription":"French (France)"}]}]},"eligibilityCriteria":{"principalInclusionCriteria":[{"id":908107,"number":1,"principalInclusionCriteria":"Age at inclusion between ≥ 16 years (Tanner 5 pubertal stage) and ≤ 45 years","principalInclusionCriteriaTranslations":[{"id":11221791,"uuid":"b7b83d24-bd58-4f48-a18c-f00df28148e3","attributeTranslation":"Age à l’inclusion entre ≥ 16 ans (stade pubertaire Tanner 5) et ≤ 45 ans","language":34,"languageDescription":"French (France)"}]},{"id":908108,"number":2,"principalInclusionCriteria":"Type 1 diabetes according to ADA criteria, with at least 1 positive autoantibody (AAC) among the following AACs: anti-islet, anti-GAD, anti-IA2, anti-ZnT8 and anti-insulin","principalInclusionCriteriaTranslations":[{"id":11221792,"uuid":"b939ee3d-be66-48cc-8ff6-b9602fb0170c","attributeTranslation":"Diabète de type 1 selon les critères ADA, avec au moins 1 auto-anticorps (AAC) positif parmi les AAC suivants : anti-îlots, anti-GAD, anti-IA2, anti-ZnT8 et anti-insuline","language":34,"languageDescription":"French (France)"}]},{"id":908109,"number":3,"principalInclusionCriteria":"Diabetes stage 3 ≤ 3 months and without ketoacidosis and without weight loss > 10% OR with fasting C-peptide ≥ 0.1nmol/L (after a delay ≥ 15days following initiation of insulin therapy).","principalInclusionCriteriaTranslations":[{"id":11221793,"uuid":"b22dd688-6ec6-4c92-bd10-73ac2958232e","attributeTranslation":"Stade 3 du diabète ≤ 3 mois et sans acido-cétose et sans perte de poids > 10% OU avec un peptide C à jeun ≥ 0,1nmol/L (après un délai ≥ 15jours suivant la mise en route de l’insulinothérapie)","language":34,"languageDescription":"French (France)"}]},{"id":908110,"number":4,"principalInclusionCriteria":"Absence of clinically significant biological abnormalities in hematology, biochemistry, liver, kidney and thyroid function tests","principalInclusionCriteriaTranslations":[{"id":11221794,"uuid":"f511c92b-1c2a-4448-9bcf-445074d1a927","attributeTranslation":"Absence d’anomalies biologiques cliniquement significatives sur les bilans hématologique, biochimique, hépatique, rénal et thyroïdien","language":34,"languageDescription":"French (France)"}]},{"id":908111,"number":5,"principalInclusionCriteria":"No documented history of heart disease and ECG without clinically significant abnormalities","principalInclusionCriteriaTranslations":[{"id":11221795,"uuid":"fdabe2b4-c7b3-4e85-90c7-7a2810b46905","attributeTranslation":"Absence d’antécédents documentés de cardiopathie et ECG sans anomalies cliniquement significatives","language":34,"languageDescription":"French (France)"}]},{"id":908112,"number":6,"principalInclusionCriteria":"Effective contraception for men and women of childbearing age > 2 weeks before the first administration of the investigational drug and throughout the treatment period (if sexually active). Sexually active women of childbearing age must use an effective contraceptive method. The following methods are acceptable: oral, injectable or implanted hormonal contraceptives. The minipill and copper IUD are tolerated28","principalInclusionCriteriaTranslations":[{"id":11221796,"uuid":"9e2cbdbc-1892-489b-bc8d-9b260a595913","attributeTranslation":"Contraception efficace chez les hommes et les femmes en âge de procréer > 2 semaines avant la première administration du médicament expérimental et pendant toute la période de traitement (si actif sexuellement). Spécifiquement pour les femmes en âge de procréer et sexuellement actives, elles doivent utiliser une méthode contraceptive efficace. Les méthodes suivantes sont acceptables : contraceptifs hormonaux par voie orale, injectables, ou implantés. La minipilule ainsi que le DIU en cuivre sont tolérés","language":34,"languageDescription":"French (France)"}]},{"id":908113,"number":7,"principalInclusionCriteria":"Free, informed and written consent, signed by the patient and the investigator, before any examination required by the trial. If the patient is a minor, the signatures of the 2 parents and the child will be collected (or the legal representative if only one parent is alive).","principalInclusionCriteriaTranslations":[{"id":11221797,"uuid":"2746bee2-6b4e-47ea-b1b6-57044f1486b9","attributeTranslation":"Consentement libre, éclairé et écrit, signé par le patient et l’investigateur, avant tout examen nécessité par l’essai.\nSi le patient est mineur, les signatures des 2 parents et de l'enfant seront recueillies (ou le représentant légal dans le cas où un seul parent est vivant).","language":34,"languageDescription":"French (France)"}]}],"principalExclusionCriteria":[{"id":1552956,"number":1,"principalExclusionCriteria":"Known contraindications to IL-2 therapy","principalExclusionCriteriaTranslations":[{"id":11221771,"uuid":"0ef4c8fb-2b60-4bfd-9eff-1a9d9a684c33","attributeTranslation":"Contre-indications connues au traitement par l’IL-2","language":34,"languageDescription":"French (France)"}]},{"id":1552957,"number":10,"principalExclusionCriteria":"Lymphopenia ≤ 1000/ mm3","principalExclusionCriteriaTranslations":[{"id":11221772,"uuid":"b2ee06de-ba96-4c28-811a-893983fc929d","attributeTranslation":"Lymphopénie ≤ 1000/ mm3","language":34,"languageDescription":"French (France)"}]},{"id":1552958,"number":11,"principalExclusionCriteria":"Presence or history of cancer cured within the last five years, except in situ cervical cancer or basal cell cancer managed at an early stage","principalExclusionCriteriaTranslations":[{"id":11221773,"uuid":"7661f741-4233-4b51-b6be-954fce0cb992","attributeTranslation":"Présence ou antécédent de cancer guéri depuis moins de cinq ans sauf cancer in situ du col de l’utérus ou basocellulaire de prise en charge à un stade précoce","language":34,"languageDescription":"French (France)"}]},{"id":1552959,"number":12,"principalExclusionCriteria":"Participation in other research relating to a clinical trial of a medicinal product for human use< 3 months","principalExclusionCriteriaTranslations":[{"id":11221774,"uuid":"ca693ad5-f9b7-44b7-a7a6-b770ae33274a","attributeTranslation":"Participation à une autre recherche relatif à un Essai Clinique de médicament à usage humain< 3 mois","language":34,"languageDescription":"French (France)"}]},{"id":1552960,"number":13,"principalExclusionCriteria":"Pregnant or breast-feeding women","principalExclusionCriteriaTranslations":[{"id":11221775,"uuid":"1b502af8-011b-425f-81c5-d040b077039a","attributeTranslation":"Femmes enceintes ou allaitantes","language":34,"languageDescription":"French (France)"}]},{"id":1552961,"number":14,"principalExclusionCriteria":"No social security coverage (as beneficiary or beneficiary's beneficiary)","principalExclusionCriteriaTranslations":[{"id":11221776,"uuid":"8e9d4c00-24e0-46a2-b08c-6899a11377dc","attributeTranslation":"Absence d’affiliation à la sécurité sociale (en tant que bénéficiaire ou ayant droit)","language":34,"languageDescription":"French (France)"}]},{"id":1552962,"number":15,"principalExclusionCriteria":"Vaccination with live attenuated virus in the last 4 weeks before starting experimental treatment and throughout the treatment phase","principalExclusionCriteriaTranslations":[{"id":11221777,"uuid":"d81ed3b0-6ca4-4e0d-8be8-26fdc6566f07","attributeTranslation":"Vaccination par virus vivant atténué au cours des 4 dernières semaines avant la mise en route du traitement expérimental et pendant toute la phase de traitement","language":34,"languageDescription":"French (France)"}]},{"id":1552963,"number":16,"principalExclusionCriteria":"Patient with active SARS-CoV-2 infection","principalExclusionCriteriaTranslations":[{"id":11221778,"uuid":"cf11845c-af3b-4fc2-994b-cafff1eb8b49","attributeTranslation":"Patient avec infection active au SARS-CoV-2","language":34,"languageDescription":"French (France)"}]},{"id":1552964,"number":17,"principalExclusionCriteria":"Patients with chronic respiratory disease","principalExclusionCriteriaTranslations":[{"id":11221779,"uuid":"05163633-ac03-45bc-83b6-992bf29659b2","attributeTranslation":"Patient avec maladie respiratoire chronique","language":34,"languageDescription":"French (France)"}]},{"id":1552965,"number":18,"principalExclusionCriteria":"Subject under legal protection (such as guardianship, curatorship or safeguarding)","principalExclusionCriteriaTranslations":[{"id":11221780,"uuid":"f5d9d1e8-6f91-4b0d-a440-21f96c875669","attributeTranslation":"Sujet sous régime de protection légale (de type tutelle, curatelle, ou sauvegarde justice)","language":34,"languageDescription":"French (France)"}]},{"id":1552966,"number":19,"principalExclusionCriteria":"Subject hospitalized without consent, unable to express consent or deprived of liberty","principalExclusionCriteriaTranslations":[{"id":11221781,"uuid":"2cc45031-d023-4b14-a102-2b359ccd0db5","attributeTranslation":"Sujet hospitalisé sans consentement, inapte à exprimer son consentement ou privé de liberté","language":34,"languageDescription":"French (France)"}]},{"id":1552967,"number":2,"principalExclusionCriteria":"Known contraindications to ciclosporin treatment","principalExclusionCriteriaTranslations":[{"id":11221782,"uuid":"1754c948-fa68-4ce2-a0df-84e2a74c0451","attributeTranslation":"Contre-indications connues au traitement par la ciclosporine","language":34,"languageDescription":"French (France)"}]},{"id":1552968,"number":3,"principalExclusionCriteria":"Presence of unauthorized treatments, i.e. cytotoxics, products known to have an impact on glycemia or to interact with trial treatments","principalExclusionCriteriaTranslations":[{"id":11221783,"uuid":"bb963bb5-b482-4f36-be83-04a48c5409c0","attributeTranslation":"Présence de traitement non-autorisé, i.e. cytotoxiques, produits connus pour leur impact sur la glycémie ou pour leurs interactions avec les traitements à l’essai","language":34,"languageDescription":"French (France)"}]},{"id":1552969,"number":4,"principalExclusionCriteria":"Patients who have received anti-diabetic treatment other than insulin for more than 3 consecutive months","principalExclusionCriteriaTranslations":[{"id":11221784,"uuid":"08069577-b075-4f2a-91c3-13ecfb1422bc","attributeTranslation":"Patients qui ont reçu un traitement antidiabétique autre que l’insuline pendant plus de 3 mois consécutifs","language":34,"languageDescription":"French (France)"}]},{"id":1552970,"number":5,"principalExclusionCriteria":"Positivity of at least one thyroid-specific antibody (anti-TPO, anti-TG or anti-TRAKS) associated with an abnormal thyroid workup (TSH, T3, or T4) at inclusion","principalExclusionCriteriaTranslations":[{"id":11221785,"uuid":"66763262-c3cb-4b3d-8e96-dd371ee21d9d","attributeTranslation":"Positivité d’au moins un des anticorps spécifiques de la thyroïde (anti-TPO, anti-TG ou anti-TRAKS) associé à un bilan thyroïdien (TSH, T3, ou T4) anormal à l’inclusion","language":34,"languageDescription":"French (France)"}]},{"id":1552971,"number":6,"principalExclusionCriteria":"Anti-transglutaminase positive at inclusion","principalExclusionCriteriaTranslations":[{"id":11221786,"uuid":"668989cf-18df-4597-bf3f-64240e605b61","attributeTranslation":"Anti-transglutaminases positifs à l’inclusion","language":34,"languageDescription":"French (France)"}]},{"id":1552972,"number":7,"principalExclusionCriteria":"EBV viral load > 2000 IU/ml","principalExclusionCriteriaTranslations":[{"id":11221787,"uuid":"9804b415-90b7-464a-aa53-e49b31b85ed1","attributeTranslation":"Charge virale EBV > 2000 UI/ml","language":34,"languageDescription":"French (France)"}]},{"id":1552973,"number":8,"principalExclusionCriteria":"CMV viral load > 400 IU/ml","principalExclusionCriteriaTranslations":[{"id":11221788,"uuid":"ac60be5f-21b8-4231-90aa-562d1caafded","attributeTranslation":"Charge virale CMV > 400 UI/ml","language":34,"languageDescription":"French (France)"}]},{"id":1552974,"number":9,"principalExclusionCriteria":"HBV, HCV or HIV infection","principalExclusionCriteriaTranslations":[{"id":11221789,"uuid":"af21ce1b-33f2-4d0f-bbac-3dc29854cf1c","attributeTranslation":"Infection par le HBV, le HCV ou le HIV","language":34,"languageDescription":"French (France)"}]}]},"endPoint":{"primaryEndPoints":[{"id":1061983,"number":1,"endPoint":"Variation in Tregs values at D70 compared with post-ciclosporin values (D63)","isPrimary":true,"endPointTranslations":[{"id":11221766,"uuid":"12179f62-ec43-464c-83a0-e0708ef74161","attributeTranslation":"Variation des valeurs de Tregs à J70 par rapport aux valeurs post-ciclosporine (J63)","language":34,"languageDescription":"French (France)"}]}],"secondaryEndPoints":[{"id":1061984,"number":1,"endPoint":"Compliance with ciclosporin and ILT-101/placebo","isPrimary":false,"endPointTranslations":[{"id":11221767,"uuid":"48430d37-d936-4f4c-8c68-682508a0ee90","attributeTranslation":"Observance à la ciclosporine et à l’ILT-101/placebo","language":34,"languageDescription":"French (France)"}]},{"id":1061985,"number":2,"endPoint":"Tolerance: tolerance will be assessed from D1 to D719 by means of a clinical examination, measurement of vital signs, a systematic biological check-up and collection of adverse events at every visit.","isPrimary":false,"endPointTranslations":[{"id":11221768,"uuid":"e8493514-aebe-4496-8812-9dea4368097e","attributeTranslation":"Tolérance : l'évaluation de la tolérance sera réalisée de J1 à J719 par le biais d’un examen clinique, la mesure des signes vitaux, un bilan biologique systématique et le recueil des évènements indésirables à toutes les visites.","language":34,"languageDescription":"French (France)"}]},{"id":1061986,"number":3,"endPoint":"Evolution of residual insulin secretion","isPrimary":false,"endPointTranslations":[{"id":11221769,"uuid":"bff0fa02-fdad-49bd-8afe-70c695af097c","attributeTranslation":"Évolution de la sécrétion résiduelle d’insuline","language":34,"languageDescription":"French (France)"}]},{"id":1061987,"number":4,"endPoint":"Change in Tregs values at M3 (J88), M6 (J179), M9 (J270), M12 (J361) and after treatment discontinuation at M18 (J536) and M24 (J719) compared to baseline and post-ciclosporin values (J63)","isPrimary":false,"endPointTranslations":[{"id":11221770,"uuid":"f4b47e81-0759-4b18-812f-4317d03e9024","attributeTranslation":"Variation des valeurs des Tregs à M3 (J88), M6 (J179), M9 (J270), M12 (J361) et après interruption du traitement à M18 (J536) et M24 (J719) comparativement à la baseline et aux valeurs post ciclosporine (J63)","language":34,"languageDescription":"French (France)"}]}]},"trialDuration":{"estimatedEndDate":"2028-04-20","estimatedRecruitmentStartDate":"2022-09-21"},"sourceOfMonetarySupport":[{"id":98246,"organisationName":"DGOS"}],"populationOfTrialSubjects":{"ageRanges":[{"id":367710,"ageRangeCategoryCode":"3","ageRangeCategory":"3"}],"ageRangeSecondaryIds":[],"clinicalTrialGroups":[{"code":"2","name":"Patients"}],"isFemaleSubjects":true,"isMaleSubjects":true,"isVulnerablePopulationSelected":true},"individualParticipantData":{"planToShareIPD":"2","planDescription":"NA"}},"protocolInformation":{"studyDesign":{"periodDetails":[]}},"scientificAdviceAndPip":{"scientificAdvices":[],"paediatricInvestigationPlan":[]},"associatedClinicalTrials":[{"id":35054,"ctNumber":"2020-005068-70","fullTitle":"NA, Etude de la réponse clinique et biologique à l’administration répétée d’interleukine-2 à faible dose chez des patients présentant un diabète de type 1 ayant gardé une sécrétion résiduelle d’insuline","sponsorAgreementOption":"OPTIONAL","sponsorAgreementOptionName":"OPTIONAL","hasDocument":false,"associatedCtDocs":[]}],"references":[],"pubmedCode":[],"pubmedUrl":[]},"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-07-24","conclusionDate":"2025-07-24","therapeuticAreas":[{"code":"20","name":"Diseases [C] - Immune System Diseases [C20]"}],"medicalConditions":[{"id":139859,"medicalCondition":"Patient with newly diagnosed (≤ 3 months) type 1 diabetes stage 3","isConditionRareDisease":false}],"sponsors":[{"id":152178,"primary":true,"publicContacts":[{"id":448980,"type":"Public","functionalName":"Pr David Klatzmann","functionalEmailAddress":"david.klatzmann@aphp.fr","telephone":"0142177461","organisation":{"id":459735,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Assistance Publique Hopitaux De Paris","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100004082","organisationLocationStatus":"Active"}}],"scientificContacts":[{"id":448981,"type":"Scientific","functionalName":"Pr David Klatzmann","functionalEmailAddress":"david.klatzmann@aphp.fr","telephone":"0142177461","organisation":{"id":459735,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Assistance Publique Hopitaux De Paris","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100004082","organisationLocationStatus":"Active"}}],"thirdParties":[],"organisation":{"id":459735,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Assistance Publique Hopitaux De Paris","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100004082","organisationLocationStatus":"Active"},"addresses":[{"id":427834,"organisation":{"id":459735,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Assistance Publique Hopitaux De Paris","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100004082","organisationLocationStatus":"Active"},"address":{"addressId":457818,"oneLine":"Porte 23, 1 Avenue Claude Vellefaux","addressLine1":"Porte 23","addressLine2":"1 Avenue Claude Vellefaux","addressLine3":"","addressLine4":"","city":"Paris Cedex 10","postcode":"75475","country":2012,"countryName":"France"},"isBusinessKeyValidated":true,"businessKey":"ORG-100004082"}],"isCommercial":false,"commercial":"Non-Commercial"}],"trialCategoryCode":"2","trialCategoryJustificationComment":"therapeutic use phase II","partOneTherapeuticAreas":[{"id":1181432,"therapeuticArea":{"code":"20","name":"Diseases [C] - Immune System Diseases [C20]"}}],"productRoleGroupInfos":[{"id":414318,"comments":"ILT-101 liquide","miaNumber":"2023_200_1_2_3_10","productRoleCode":"1","productRoleName":"Test","products":[{"id":556491,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11428062","productPharmForm":"SOLUTION FOR INJECTION","euMpNumber":"PRD11428062","prodAuthStatus":1,"prodName":"ILT-101 liquide","pharmForm":"SOLUTION FOR INJECTION","sponsorProductCode":"ILT-101 ","activeSubstanceName":"ALDESLEUKIN","euSubstNumber":"SUB05303MIG","nameOrg":"ILTOO PHARMA","productSubstances":[{"productPk":"11428062","substancePk":"376734","nameOrg":"ILTOO PHARMA","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"ALDESLEUKIN","substanceEvCode":"SUB05303MIG"}],"atcCode":"L03AC01","atcName":"ALDESLEUKIN","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"Munit million units","maxDailyDoseAmount":"1","doseUomTotal":"Munit million units","maxTotalDoseAmount":"46","maxTreatmentPeriod":12,"timeUnitCode":"3","evCode":"PRD11428062","sponsorProductCodeEdit":"ILT-101 ","miaNumber":"2023_200_1_2_3_10","devices":[],"characteristics":["7","4"],"routes":["INTRAVENOUS"],"allSubstancesChemicals":false,"productName":"ILT-101 liquide","jsonActiveSubstanceNames":"aldesleukin","pharmaceuticalFormDisplay":"SOLUTION FOR INJECTION"}]},{"id":414316,"comments":"CICLOSPORIN\r","productRoleCode":"1","productRoleName":"Test","products":[{"id":556489,"part1MpRoleTypeCode":"2","productDictionaryInfo":{"productPharmForm":"PHF00007MIG","euMpNumber":"SCP138048","marketingAuthNumber":"-","prodAuthStatus":2,"activeSubstanceName":"CICLOSPORIN","euSubstNumber":"SUB06250MIG","productSubstances":[{"substancePk":"422835","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"CICLOSPORIN","substanceEvCode":"SUB06250MIG","synonyms":["CYCLOSPORIN A","CYCLOSPORINE","CICLOSPORINE","CYCLOSPORIN"]}],"atcCode":"L04AD01","atcName":"CICLOSPORIN\r","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"500","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"30","productChangedRelationMA":false,"maxTreatmentPeriod":60,"timeUnitCode":"1","scientificProductEvCode":"SCP138048","scientificProductPharmEvCode":"PHF00007MIG","devices":[],"characteristics":["6"],"routes":["ORAL USE"],"allSubstancesChemicals":true,"productName":"CICLOSPORIN\r","jsonActiveSubstanceNames":"ciclosporin","pharmaceuticalFormDisplay":"PHF00007MIG"}]},{"id":414317,"comments":"Placebo of ILT-101","miaNumber":"2023_200_1_2_3_10","productRoleCode":"3","productRoleName":"Placebo","products":[{"id":556490,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPharmForm":"N/A","euMpNumber":"N/A","marketingAuthNumber":"N/A","prodName":"Placebo of ILT-101","pharmForm":"N/A","activeSubstanceName":"N/A","euSubstNumber":"N/A","productOtherName":"N/A","authorisationCountryCode":"IS","nameOrg":"N/A","sponsorSubstanceCode":"N/A","atcCode":"N/A","atcName":"N/A","atcTermLevel":"N/A","activeSubstanceOtherDescriptiveName":"N/A"},"isPaediatricFormulation":false,"mpRoleInTrial":"3","timeUnitCode":"2","evCode":"N/A","miaNumber":"2023_200_1_2_3_10","devices":[],"characteristics":[],"routes":[],"allSubstancesChemicals":false,"productName":"Placebo of ILT-101","jsonActiveSubstanceNames":"n/a","pharmaceuticalFormDisplay":"N/A"}]}],"isLowIntervention":false},"authorizedPartsII":[{"id":172918,"mscId":32378,"mscInfo":{"id":32378,"clinicalTrialId":14897,"countryOrganisationId":2012,"reportingStatusCode":"Authorised","fromDate":"2024-05-30","toDate":"2024-05-30","isProposedRms":true,"countryName":"France","organisationInfo":{},"firstDecisionDate":"2024-07-19","trialStatus":"Authorised","trialPeriod":[{"id":34487,"trialStartDate":"2022-09-21","fromDate":"2024-09-13"},{"id":34488,"trialStartDate":"2022-09-21","fromDate":"2024-09-13"}],"trialRecruitmentPeriod":[{"id":44724,"recruitmentStartDate":"2022-09-21","fromDate":"2024-09-13"},{"id":44725,"recruitmentStartDate":"2022-09-21","fromDate":"2024-09-13"},{"id":118118,"recruitmentStartDate":"2022-09-21","recruitmentEndDate":"2025-11-27","fromDate":"2026-07-27"},{"id":118119,"recruitmentStartDate":"2022-09-21","recruitmentEndDate":"2025-11-27","fromDate":"2026-07-27"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":46147,"trialStartDate":"2022-09-21","fromDate":"2024-09-13"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2022-09-21","recruitmentEndDate":"2025-11-27"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":44417,"mscId":32378,"trialStatus":"Authorised","trialStatusDate":"2024-07-19T16:48:13.845"},{"id":41848,"mscId":32378,"trialStatus":"Under evaluation","trialStatusDate":"2024-07-04T10:37:04.365"}],"applicationTypeMsc":"1","mscName":"France","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-01-28","decision":"authorized","decisionDate":"2024-07-19"},"decisionDate":"2024-07-19","recruitmentSubjectCount":24,"trialSites":[{"id":1116600,"organisationAddressInfo":{"id":469787,"organisation":{"id":502155,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Assistance Publique Hopitaux De Paris","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100004082","organisationLocationStatus":"Active"},"address":{"addressId":503680,"oneLine":"27 Rue Du Faubourg Saint Jacques","addressLine1":"27 Rue Du Faubourg Saint Jacques","addressLine2":"","addressLine3":"","addressLine4":"","city":"Paris","postcode":"75014","country":2012,"countryName":"France"},"phone":"0176535583","email":"roberto.mallone@inserm.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100004082"},"personInfo":{"id":1247902,"firstName":"Roberto","lastName":"Mallone","telephone":"0176535583","email":"roberto.mallone@inserm.fr","title":"2"},"departmentName":"Service de Diabétologie"},{"id":1116601,"organisationAddressInfo":{"id":469781,"organisation":{"id":502149,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Assistance Publique Hopitaux De Paris","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100004082","organisationLocationStatus":"Active"},"address":{"addressId":503674,"oneLine":"43 Boulevard De L Hopital","addressLine1":"43 Boulevard De L Hopital","addressLine2":"","addressLine3":"","addressLine4":"","city":"Paris","postcode":"75013","country":2012,"countryName":"France"},"phone":"0142165792","email":"chloe.amouyal@aphp.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100004082"},"personInfo":{"id":1247903,"firstName":"Chloé","lastName":"Amouyal","telephone":"0142165792","email":"chloe.amouyal@aphp.fr","title":"1"},"departmentName":"Service de Diabétologie"},{"id":1116603,"organisationAddressInfo":{"id":469791,"organisation":{"id":502159,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Assistance Publique Hopitaux De Paris","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100004082","organisationLocationStatus":"Active"},"address":{"addressId":503684,"oneLine":"47 Boulevard De L Hopital","addressLine1":"47 Boulevard De L Hopital","addressLine2":"","addressLine3":"","addressLine4":"","city":"Paris Cedex 13","postcode":"75651","country":2012,"countryName":"France"},"phone":"0142178533","email":"chloe.amouyal@aphp.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100004082"},"personInfo":{"id":1247905,"firstName":"Chloé","lastName":"AMOUYAL","telephone":"0142178533","email":"chloe.amouyal@aphp.fr","title":"1"},"departmentName":"CIC Pitié-Salpêtrière"},{"id":1116602,"organisationAddressInfo":{"id":469777,"organisation":{"id":502145,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Assistance Publique Hopitaux De Paris","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100004082","organisationLocationStatus":"Active"},"address":{"addressId":503670,"oneLine":"47 Boulevard De L Hopital","addressLine1":"47 Boulevard De L Hopital","addressLine2":"","addressLine3":"","addressLine4":"","city":"Paris Cedex 13","postcode":"75651","country":2012,"countryName":"France"},"phone":"0142177461","email":"david.klatzmann@aphp.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100004082"},"personInfo":{"id":1247904,"firstName":"David","lastName":"KLATZMANN","telephone":"0142177461","email":"david.klatzmann@aphp.fr","title":"2"},"departmentName":"Service de Biothérapies"}],"applicationStatusCode":"Authorised"}],"applicationInfo":[{"id":24996,"type":"INITIAL","status":"Authorised","ctNumber":"2024-514043-29-00","trialStatus":"Authorised","submissionDate":"2024-07-04","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-07-19"},"partIIInfo":[{"id":104597,"mscId":32378,"mscInfo":{"id":32378,"mscName":"France","countryOrganisationId":2012,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-07-15","decision":"authorized","decisionDate":"2024-07-19","reportingStatusCode":"Authorised","countryName":"France","trialStatus":"Authorised","firstDecisionDate":"2024-07-19"},"applicationStatusCode":"Authorised"}],"decisionDate":"2024-07-19","ctMSCsByApplication":[{"id":32378,"mscName":"France","reportingStatusCode":"Authorised"}],"businessKey":"IN","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":29928,"applicationId":24996,"mscId":32378,"mscName":"France","decisionDate":"2024-07-19T16:48:14.133","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":104597,"part1Id":37215,"applicationType":"INITIAL","isRMS":true}],"productRoleGroupDocument":[{"documentUuid":"e468bd39-c8fd-42f6-996b-e0b06d0ac2f6","productRoleGroupId":141881}]},{"id":43169,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-514043-29-00","trialStatus":"Authorised","submissionDate":"2024-12-09","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-02-06"},"partIIInfo":[{"id":172918,"mscId":32378,"mscInfo":{"id":32378,"mscName":"France","countryOrganisationId":2012,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-01-28","decision":"authorized","decisionDate":"2024-07-19","reportingStatusCode":"Authorised","countryName":"France","trialStatus":"Authorised","firstDecisionDate":"2024-07-19"},"applicationStatusCode":"Authorised"}],"decisionDate":"2025-02-06","ctMSCsByApplication":[{"id":32378,"mscName":"France","reportingStatusCode":"Authorised"}],"businessKey":"SM-1","modScope":"PART_I_AND_PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":56774,"applicationId":43169,"mscId":32378,"mscName":"France","decisionDate":"2025-02-06T21:01:30.573","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":172918,"part1Id":70592,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true}],"productRoleGroupDocument":[{"documentUuid":"835ddf1a-6cf4-404f-8f3e-6464d11f642e","productRoleGroupId":220908}]},{"id":56920,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-514043-29-00","trialStatus":"Authorised","submissionDate":"2025-06-12","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-07-24"},"partIIInfo":[],"decisionDate":"2025-07-25","ctMSCsByApplication":[{"id":32378,"mscName":"France","reportingStatusCode":"Authorised"}],"businessKey":"SM-2","modScope":"PART_I","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":82048,"applicationId":56920,"mscId":32378,"mscName":"France","decisionDate":"2025-07-25T12:12:41.743","decision":"authorized","eventType":"decision","part1Id":90464,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true}],"productRoleGroupDocument":[{"documentUuid":"835ddf1a-6cf4-404f-8f3e-6464d11f642e","productRoleGroupId":281318}]},{"id":83548,"type":"NON SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-514043-29-00","trialStatus":"Authorised","submissionDate":"2026-04-30","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-07-24"},"partIIInfo":[],"decisionDate":"2026-04-30","ctMSCsByApplication":[{"id":32378,"mscName":"France","reportingStatusCode":"Authorised"}],"businessKey":"NSM-1","modScope":"PART_I","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":121945,"applicationId":83548,"mscId":32378,"mscName":"France","decisionDate":"2026-04-30T15:24:15.853","decision":"authorized","eventType":"decision","part1Id":127884,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":true}],"productRoleGroupDocument":[{"documentUuid":"835ddf1a-6cf4-404f-8f3e-6464d11f642e","productRoleGroupId":396053}]},{"id":87693,"type":"NON SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-514043-29-00","trialStatus":"Authorised","submissionDate":"2026-06-18","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-07-24"},"partIIInfo":[],"decisionDate":"2026-06-18","ctMSCsByApplication":[{"id":32378,"mscName":"France","reportingStatusCode":"Authorised"}],"businessKey":"NSM-2","modScope":"PART_I","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":129259,"applicationId":87693,"mscId":32378,"mscName":"France","decisionDate":"2026-06-18T14:19:44.282","decision":"authorized","eventType":"decision","part1Id":133894,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":true}],"productRoleGroupDocument":[{"documentUuid":"835ddf1a-6cf4-404f-8f3e-6464d11f642e","productRoleGroupId":414316}]}],"trialGlobalEnd":[],"memberStatesConcerned":[{"mscName":"France","mscId":32378,"firstDecisionDate":"2024-07-19T16:48:14.133","lastDecisionDate":"2025-02-06T21:01:30.573","mscPublicStatusCode":5}],"eudraCt":{"isTransitioned":true,"eudraCtCode":"2020-005068-70"}},"events":{"temporaryHaltList":[],"trialEvents":[{"mscId":32378,"mscName":"France","events":[{"notificationType":"START_OF_TRIAL","date":"2022-09-21"},{"notificationType":"START_OF_RECRUITMENT","date":"2022-09-21"},{"notificationType":"END_OF_RECRUITMENT","date":"2025-11-27"}]}],"unexpectedEvents":[],"seriousBreaches":[],"urgentSafetyMeasures":[]},"results":{},"documents":[{"title":"K1_Recruitment arrangements","uuid":"8b4334fe-7b16-4f3e-b713-3700e8edc72a","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":172918,"manualVersion":"2.0","systemVersion":"2"},{"title":"L1_SIS and ICF_ADULT","uuid":"3a4ed0f4-b13a-4238-9484-55e2950fb0bd","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":172918,"manualVersion":"8","systemVersion":"2"},{"title":"L1_SIS and ICF_AUTORITE PARENTALE","uuid":"5d42d249-908a-45bd-bf26-bd0b93cbacc4","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":34,"fileType":"PDF","associatedEntityId":172918,"manualVersion":"8","systemVersion":"2"},{"title":"L1_SIS and ICF_MINOR","uuid":"922a0546-979d-4b83-a5b1-fa8fc9aacb2d","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":172918,"manualVersion":"8","systemVersion":"2"},{"title":"2024-514043-29-00_SoC-SM01_Protocole-NIFC","uuid":"fd81672a-9d20-47dd-a540-8dd00ee78b21","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":172918,"manualVersion":"1","systemVersion":"1"},{"title":"D1_Protocole_2024-514043-29-00_for publication_clean","uuid":"95b3b6c4-bbb2-4d37-8d99-4794475007ca","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":133894,"manualVersion":"9","systemVersion":"2.01"},{"title":"2024-514043-29-00_SoC-SM01_Protocole-NIFC","uuid":"7292ba0c-6d80-4716-8a6f-0ea60030fc59","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":133894,"manualVersion":"2","systemVersion":"1.01"},{"title":"D1_Protocol synopsis_FR_2024-514043-29-00_DFIL-REP_clean","uuid":"6ec813c1-421d-4e28-a788-fd25df687f63","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":133894,"manualVersion":"9","systemVersion":"2.01"},{"title":"E2_SmPC_NEORAL","uuid":"835ddf1a-6cf4-404f-8f3e-6464d11f642e","documentType":"19","documentTypeLabel":"Summary of Product Characteristics (SmPC) (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":414316,"manualVersion":"2","systemVersion":"2"}],"trialRegion":"EEA","trialRegionCode":1,"correctiveMeasures":[]}